Format
Sort by
Items per page

Send to

Choose Destination

Links from Gene

Items: 1 to 20 of 461

1.

Postinjury Induction of Activated ErbB2 Selectively Hyperactivates Denervated Schwann Cells and Promotes Robust Dorsal Root Axon Regeneration.

Han SB, Kim H, Lee H, Grove M, Smith GM, Son YJ.

J Neurosci. 2017 Nov 8;37(45):10955-10970. doi: 10.1523/JNEUROSCI.0903-17.2017. Epub 2017 Oct 5.

2.

[Over-expressed HER2 enhances proliferation, migration and invasion of melanoma B16 cells].

Xia W, Lu C, Wang X, Zhu W, Zhang H.

Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2017 Aug;33(8):1067-1072. Chinese.

PMID:
28871948
3.

CD73 Promotes Resistance to HER2/ErbB2 Antibody Therapy.

Turcotte M, Allard D, Mittal D, Bareche Y, Buisseret L, José V, Pommey S, Delisle V, Loi S, Joensuu H, Kellokumpu-Lehtinen PL, Sotiriou C, Smyth MJ, Stagg J.

Cancer Res. 2017 Oct 15;77(20):5652-5663. doi: 10.1158/0008-5472.CAN-17-0707. Epub 2017 Aug 30.

4.

Lack of interaction between ErbB2 and insulin receptor substrate signaling in breast cancer.

Farabaugh SM, Chan BT, Cui X, Dearth RK, Lee AV.

Cell Commun Signal. 2016 Oct 21;14(1):25.

5.

Echocardiographic Characterization of a Murine Model of Hypertrophic Obstructive Cardiomyopathy Induced by Cardiac-specific Overexpression of Epidermal Growth Factor Receptor 2.

Sørensen LL, Bedja D, Sysa-Shah P, Liu H, Maxwell A, Yi X, Pozios I, Olsen NT, Abraham TP, Abraham R, Gabrielson K.

Comp Med. 2016;66(4):268-77.

6.

Trastuzumab improves tumor perfusion and vascular delivery of cytotoxic therapy in a murine model of HER2+ breast cancer: preliminary results.

Sorace AG, Quarles CC, Whisenant JG, Hanker AB, McIntyre JO, Sanchez VM, Yankeelov TE.

Breast Cancer Res Treat. 2016 Jan;155(2):273-84. doi: 10.1007/s10549-016-3680-8. Epub 2016 Jan 20.

7.

Bidirectional cross-regulation between ErbB2 and β-adrenergic signalling pathways.

Sysa-Shah P, Tocchetti CG, Gupta M, Rainer PP, Shen X, Kang BH, Belmonte F, Li J, Xu Y, Guo X, Bedja D, Gao WD, Paolocci N, Rath R, Sawyer DB, Naga Prasad SV, Gabrielson K.

Cardiovasc Res. 2016 Mar 1;109(3):358-73. doi: 10.1093/cvr/cvv274. Epub 2015 Dec 21.

8.

Biomarkers of aging, life span and spontaneous carcinogenesis in the wild type and HER-2 transgenic FVB/N female mice.

Panchenko AV, Popovich IG, Trashkov AP, Egormin PA, Yurova MN, Tyndyk ML, Gubareva EA, Artyukin IN, Vasiliev AG, Khaitsev NV, Zabezhinski MA, Anisimov VN.

Biogerontology. 2016 Apr;17(2):317-24. doi: 10.1007/s10522-015-9611-y. Epub 2015 Sep 30.

PMID:
26423570
9.

ERBB2 triggers mammalian heart regeneration by promoting cardiomyocyte dedifferentiation and proliferation.

D'Uva G, Aharonov A, Lauriola M, Kain D, Yahalom-Ronen Y, Carvalho S, Weisinger K, Bassat E, Rajchman D, Yifa O, Lysenko M, Konfino T, Hegesh J, Brenner O, Neeman M, Yarden Y, Leor J, Sarig R, Harvey RP, Tzahor E.

Nat Cell Biol. 2015 May;17(5):627-38. doi: 10.1038/ncb3149. Epub 2015 Apr 6.

PMID:
25848746
10.

Use of the disulfiram/copper complex for breast cancer chemoprevention in MMTV-erbB2 transgenic mice.

Yang Y, Deng Q, Feng X, Sun J.

Mol Med Rep. 2015 Jul;12(1):746-52. doi: 10.3892/mmr.2015.3426. Epub 2015 Mar 4.

PMID:
25738885
11.

Krt6a-positive mammary epithelial progenitors are not at increased vulnerability to tumorigenesis initiated by ErbB2.

Holloway KR, Sinha VC, Toneff MJ, Bu W, Hilsenbeck SG, Li Y.

PLoS One. 2015 Jan 30;10(1):e0117239. doi: 10.1371/journal.pone.0117239. eCollection 2015.

12.

Mammary cells with active Wnt signaling resist ErbB2-induced tumorigenesis.

Bu W, Zhang X, Dai H, Huang S, Li Y.

PLoS One. 2013 Nov 12;8(11):e78720. doi: 10.1371/journal.pone.0078720. eCollection 2013.

13.

β-Catenin signaling is a critical event in ErbB2-mediated mammary tumor progression.

Schade B, Lesurf R, Sanguin-Gendreau V, Bui T, Deblois G, O'Toole SA, Millar EK, Zardawi SJ, Lopez-Knowles E, Sutherland RL, Giguère V, Kahn M, Hallett M, Muller WJ.

Cancer Res. 2013 Jul 15;73(14):4474-87. doi: 10.1158/0008-5472.CAN-12-3925. Epub 2013 May 29.

14.

Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2.

Greulich H, Kaplan B, Mertins P, Chen TH, Tanaka KE, Yun CH, Zhang X, Lee SH, Cho J, Ambrogio L, Liao R, Imielinski M, Banerji S, Berger AH, Lawrence MS, Zhang J, Pho NH, Walker SR, Winckler W, Getz G, Frank D, Hahn WC, Eck MJ, Mani DR, Jaffe JD, Carr SA, Wong KK, Meyerson M.

Proc Natl Acad Sci U S A. 2012 Sep 4;109(36):14476-81. doi: 10.1073/pnas.1203201109. Epub 2012 Aug 20.

15.

In vivo method to monitor changes in HER2 expression using near-infrared fluorescence imaging.

Hassan M, Chernomordik V, Zielinski R, Ardeshirpour Y, Capala J, Gandjbakhche A.

Mol Imaging. 2012 Jun;11(3):177-86.

16.

A CpG oligodeoxynucleotide potentiates the anti-tumor effect of HSP65-Her2 fusion protein against Her2 positive B16 melanoma in mice.

Yan Y, Cao Z, Yang M, Li H, Wei H, Fu Y, Song D, Wang L, Yu Y.

Int Immunopharmacol. 2012 Feb;12(2):402-7. doi: 10.1016/j.intimp.2011.12.013. Epub 2012 Jan 2.

PMID:
22222115
17.

Atorvastatin modulates anti-proliferative and pro-proliferative signals in Her2/neu-positive mammary cancer.

Riganti C, Pinto H, Bolli E, Belisario DC, Calogero RA, Bosia A, Cavallo F.

Biochem Pharmacol. 2011 Nov 1;82(9):1079-89. doi: 10.1016/j.bcp.2011.07.079. Epub 2011 Jul 23.

18.

[Experimental study of c-erbB2 on the fertilization in mouse].

Zhong ZS, Wu LF, Zheng YH, Fang L.

Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2003 Feb;19(1):60-4. Chinese.

PMID:
21207860
19.

Proteomic characterization of Her2/neu-overexpressing breast cancer cells.

Chen H, Pimienta G, Gu Y, Sun X, Hu J, Kim MS, Chaerkady R, Gucek M, Cole RN, Sukumar S, Pandey A.

Proteomics. 2010 Nov;10(21):3800-10. doi: 10.1002/pmic.201000297.

20.

Somatic expression of PyMT or activated ErbB2 induces estrogen-independent mammary tumorigenesis.

Toneff MJ, Du Z, Dong J, Huang J, Sinai P, Forman J, Hilsenbeck S, Schiff R, Huang S, Li Y.

Neoplasia. 2010 Sep;12(9):718-26.

Supplemental Content

Support Center